Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
Jared M. Baeten, Thesla Palanee‐Phillips, Nyaradzo Mgodi, et al.
The Lancet HIV (2021) Vol. 8, Iss. 2, pp. e87-e95
Open Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

Update and latest advances in antiretroviral therapy
Luis Menéndez‐Arias, Rafaël Delgado
Trends in Pharmacological Sciences (2021) Vol. 43, Iss. 1, pp. 16-29
Open Access | Times Cited: 145
Approved HIV reverse transcriptase inhibitors in the past decade
Guangdi Li, Yali Wang, Erik De Clercq
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1567-1590
Open Access | Times Cited: 78
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial
Gonasagrie Nair, Connie Celum, Daniel Szydlo, et al.
The Lancet HIV (2023) Vol. 10, Iss. 12, pp. e779-e789
Open Access | Times Cited: 33
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities
Jessica E. Haberer, Andrew Mujugira, Kenneth H. Mayer
The Lancet HIV (2023) Vol. 10, Iss. 6, pp. e404-e411
Closed Access | Times Cited: 27
Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
Mohammad Ullah Nayan, Brady Sillman, Mahmudul Hasan, et al.
Advanced Drug Delivery Reviews (2023) Vol. 200, pp. 115009-115009
Open Access | Times Cited: 26
Preferences and acceptability for long‐acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya
Nafisa J. Wara, Rufaro Mvududu, Mary M. Marwa, et al.
Journal of the International AIDS Society (2023) Vol. 26, Iss. 5
Open Access | Times Cited: 24
Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development
Barbara Friedland, Holly Gundacker, Sharon L. Achilles, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0312957-e0312957
Open Access | Times Cited: 1
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother–infant pairs (MTN-043): a phase 3B, open-label, randomised trial
Lisa Noguchi, Maxensia Owor, Nyaradzo Mgodi, et al.
The Lancet HIV (2025)
Closed Access | Times Cited: 1
Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap
Dvora Joseph Davey, Linda‐Gail Bekker, Elizabeth A. Bukusi, et al.
The Lancet HIV (2022) Vol. 9, Iss. 3, pp. e214-e222
Open Access | Times Cited: 34
Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges
Vivek Agrahari, Sharon M. Anderson, M. Melissa Peet, et al.
Expert Opinion on Drug Delivery (2022) Vol. 19, Iss. 10, pp. 1365-1380
Open Access | Times Cited: 34
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data
Reshma Kassanjee, Alex Welte, Kennedy Otwombe, et al.
The Lancet HIV (2022) Vol. 9, Iss. 11, pp. e781-e790
Open Access | Times Cited: 30
Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention
Sai Archana Krovi, Leah M. Johnson, Ellen Luecke, et al.
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113849-113849
Closed Access | Times Cited: 40
Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world
Kathleen Ridgeway, Elizabeth Montgomery, Kevin Smith, et al.
Contraception (2021) Vol. 106, pp. 16-33
Open Access | Times Cited: 33
Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
Urvi M. Parikh, Catherine A. Koss, John W. Mellors
Current HIV/AIDS Reports (2022) Vol. 19, Iss. 5, pp. 384-393
Open Access | Times Cited: 26
Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV
Morgan M. Philbin, Amaya Perez‐Brumer
Current Opinion in HIV and AIDS (2022) Vol. 17, Iss. 2, pp. 72-88
Open Access | Times Cited: 25
How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub‐Saharan Africa: a mixed methods analysis
Sarah T. Roberts, Noah Mancuso, Kristin Williams, et al.
Journal of the International AIDS Society (2023) Vol. 26, Iss. 11
Open Access | Times Cited: 14
Polymer Delivery Systems for Long-Acting Antiretroviral Drugs
Mohammad Ullah Nayan, Sudipta Panja, Ashrafi Sultana, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 183-183
Open Access | Times Cited: 6
Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists
Elizabeth M Sherman, Allison L. Agwu, Juan Ambrosioni, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 7, pp. 494-538
Open Access | Times Cited: 5
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
Urvi M. Parikh, John W. Mellors
Current Opinion in HIV and AIDS (2022) Vol. 17, Iss. 4, pp. 213-221
Open Access | Times Cited: 20
Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial
Kenneth Ngure, Erica N. Browne, Krishnaveni Reddy, et al.
AIDS and Behavior (2024) Vol. 28, Iss. 9, pp. 2990-3000
Closed Access | Times Cited: 4
Women-specific routes of administration for drugs: A critical overview
José das Neves, Fernando Notario-Pérez, Bruno Sarmento
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113865-113865
Closed Access | Times Cited: 25
An Open Letter on Advancing HIV prevention: Augmenting an ecosystem-based approach to understand prevention decision-making
Nishan Gantayat, James A. Baer, Alok Gangaramany, et al.
Gates Open Research (2025) Vol. 8, pp. 73-73
Open Access
Engineering vaginal film platform for mucoadhesion and sustained drug release for HIV-1 prevention
Jing Li, Sravan Kumar Patel, Yvonne Sweeney, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 696-707
Closed Access
Update on HIV Chemoprevention
Cheríe Blair, Mary Catherine Cambou, Raphael J. Landovitz
Annual Review of Medicine (2025) Vol. 76, Iss. 1, pp. 43-56
Closed Access
Estimated contributions and future mitigation strategies for HIV risk around funeral practices in western Kenya: a mathematical modeling study
Samuel Mwalili, Duncan Gathungu, Josiline Chemutai, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top